Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting StentsResults From a Large Prospective Multicenter Registry—STENT Group
Charles A. Simonton, MD, FACC, FSCAI*,*,
Bruce Brodie, MD ,
Barrett Cheek, MD ,
Fred Krainin, MD ,
Chris Metzger, MD||,
James Hermiller, MD#,
Stanley Juk, MD**,
Peter Duffy, MD,
Angela Humphrey, MS,
Marcy Nussbaum, MS,
Sherry Laurent, PhD STENT Group
* Carolinas Heart Institute, Carolinas Medical Center, Charlotte, North Carolina
LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina
High Point Regional Health System, High Point, North Carolina
McLeod Regional Medical Center, Florence, South Carolina
|| Holston Valley Medical Center, Kingsport, Tennessee
# Indiana Heart Institute, Indianapolis, Indiana
** Sisters of Charity Providence Hospitals, Columbia, South Carolina
Moore Regional Hospital, Pinehurst, North Carolina
R. Stuart Dickson Institute for Health Studies, Carolinas Medical Center, Charlotte, North Carolina
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Derivation of Study Population
Derivation of study sample from percutaneous coronary interventions (PCI) done between May 2003 and September 2005. *Includes patients treated with bare-metal stents or any combination of drug-eluting and/or bare-metal stents. PES = paclitaxel-eluting stent; SES = sirolimus-eluting stent.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Freedom From TVR and MACE for PES and SES
Kaplan-Meier proportional hazards time to (A) target vessel revascularization (TVR) and (B) major adverse cardiac events (MACE) (death, myocardial infarction, or TVR) comparing SES and PES groups (unadjusted). CI = confidence interval; HR = hazard ratio; other abbreviations as in Figure 1.
|
|
View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Comparative Unadjusted Rates of MACE for Overall Population and Subgroups
Hazard ratios (HRs) of stent type for MACE in the overall patient population and specified subgroups. *These 3 subgroups show statistically significant unadjusted HRs. However, the male and prior coronary artery bypass graft (CABG) subgroups become nonsignificant when adjusted by propensity score. Saphenous vein graph (SVG) lesions remain significant (HR 2.38; 95% CI 1.21 to 4.69; p = 0.012). LAD = left anterior descending artery; STEMI = ST-segment elevation myocardial infarction; other abbreviations as in Figures 1 and 2.
|
|
|
